Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse as augmentation therapy for Major Depressive Disorder
NCT00905424Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2009
- Primary completion
- Aug 2010
- Countries
- 1
01
Overview
A Phase 2 trial of lisdexamfetamine in major depressive disorder (MDD), sponsored by Takeda. Started Jul 2009; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00905424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00905424.